The current financial score of Ocular Therapeutix Inc is 6.52. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 13.47M, representing a year-over-year increase of 0.12%, while its net profit experienced a year-over-year increase of 16.15%.
The current valuation score of Ocular Therapeutix Inc is 7.49. Its current P/E ratio is -6.96, which is -65.67% below the recent high of -2.39 and -61.48% above the recent low of -11.23.
The current earnings forecast score of Ocular Therapeutix Inc is 8.67. The average price target is 26.73, with a high of 34.00 and a low of 18.00.
The current price momentum score of Ocular Therapeutix Inc is 3.43. Currently, the stock price is trading between the resistance level at 11.06 and the support level at 9.36, making it suitable for range-bound swing trading.
The current institutional shareholding score of Ocular Therapeutix Inc is 10.00. The latest institutional shareholding proportion is 97.04%, representing a quarter-over-quarter increase of 9.08%. The largest institutional shareholder is James Simons, holding a total of 378.75K shares, representing 0.01% of shares outstanding, with 1.69% increase in holdings.
The current risk assessment score of Ocular Therapeutix Inc is 5.69. The company's beta value is 0.90. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.